Biotech · Private company
Neurotech Pharmaceuticals
Track this companyFree. Adds Neurotech Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials112 recruiting or active
Pipeline programs19From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline19
- CHFMPhase 3 · Macular Telangiectasia Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- M-CHFMPhase 3 · Macular Telangiectasia Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- NT-501Phase 3 · Macular Telangiectasia Type 2 (MacTel)ClinicalTrials.gov · fetched Nov 12, 2026
- NT-501Phase 3 · Macular Telangiectasia Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- ShamPhase 3 · Macular Telangiectasia Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- Sham ProcedurePhase 3 · Macular Telangiectasia Type 2 (MacTel)ClinicalTrials.gov · fetched Nov 12, 2026
- Ciliary neurotrophic factor (CNTF)Phase 2 · MacTel (Macular Telangiectasia) Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- Eylea® injected intravitreally administered every 8 weeksPhase 2 · Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- High Dose NT-501Phase 2 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- High Dose NT-501 implantPhase 2 · Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry StageClinicalTrials.gov · fetched Nov 12, 2026
- Low Dose NT-501Phase 2 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- Low Dose NT-501 implantPhase 2 · Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry StageClinicalTrials.gov · fetched Nov 12, 2026
- NT-501Phase 2 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- NT-501 CNTF implantPhase 2 · Macular Telangiectasia Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- NT-503-3 ECT implantationPhase 2 · Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ShamPhase 2 · Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry StageClinicalTrials.gov · fetched Nov 12, 2026
- ShamPhase 2 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- SurgeryPhase 2 · MacTel (Macular Telangiectasia) Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- NT-501/revakinagene taroretcel-lweyMacular Telangiectasia Type 2 (MacTel)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure ParticipantsPHASE4 · RECRUITING · started Nov 21, 2025ClinicalTrials.gov NCT06971939 · fetched Nov 12, 2026
- A Study to Determine the Safety and Efficacy of NT-501 With M-CHFMPHASE3 · RECRUITING · started Mar 6, 2025ClinicalTrials.gov NCT06397131 · fetched Nov 12, 2026
- Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2PHASE2 · COMPLETED · started Jul 21, 2021ClinicalTrials.gov NCT04729972 · fetched Nov 12, 2026
- A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol BPHASE3 · COMPLETED · started Jan 22, 2018ClinicalTrials.gov NCT03319849 · fetched Nov 12, 2026
- A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol APHASE3 · COMPLETED · started Nov 24, 2017ClinicalTrials.gov NCT03316300 · fetched Nov 12, 2026
- Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)PHASE2 · COMPLETED · started May 12, 2017ClinicalTrials.gov NCT03071965 · fetched Nov 12, 2026
- Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)PHASE1_PHASE2 · TERMINATED · started Sep 1, 2014ClinicalTrials.gov NCT02228304 · fetched Nov 12, 2026
- Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis PigmentosaPHASE2 · COMPLETED · started Jan 1, 2012ClinicalTrials.gov NCT01530659 · fetched Nov 12, 2026
- A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis PigmentosaPHASE2 · COMPLETED · started Jan 22, 2007ClinicalTrials.gov NCT00447980 · fetched Nov 12, 2026
- A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis PigmentosaPHASE2 · COMPLETED · started Jan 8, 2007ClinicalTrials.gov NCT00447993 · fetched Nov 12, 2026
- A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular DegenerationPHASE2 · COMPLETED · started Jan 5, 2007ClinicalTrials.gov NCT00447954 · fetched Nov 12, 2026